CNBC April 25, 2024
Key Points
– Merck reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products.
– The pharmaceutical giant also raised and narrowed its full-year revenue and adjusted earnings outlooks.
– Those results come as Merck shows substantial progress in preparing for Keytruda’s patent expiration in 2028.
Merck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products.
The pharmaceutical giant also raised and narrowed its full-year revenue and adjusted earnings forecasts. Merck now expects 2024 sales to come in between $63.1 billion and $64.3 billion, up from previous guidance of $62.7 to...
Today's Sponsors
Today's Sponsor